JSJames Sondheimer

James Sondheimer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


James Sondheimer has a total of 185 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Defining Kidney Health Dimensions and Their Associations with Adverse Outcomes in Persons with Diabetes and CKD

    by Vanessa-Giselle Peschard, Rebecca Scherzer, Michelle M. Estrella, Mark J. Sarnak, Simon B. Ascher, James Lash, Joseph V. Bonventre, Jason H. Greenberg, Orlando M. Gutierrez, Jeffrey R. Schelling, et al.

    Key Points: We identified three kidney health dimensions using 17 urine and plasma biomarkers across two cohorts of persons with diabetes and CKD. Worse scores for tubule injury, tubule function, and systemic inflammation/filtration were associated with a higher risk of CKD progression and death. A multibiomarker approach could help capture tubulointerstitial health in persons with diabetes and CKD. Background: Individual kidney tubule biomarkers are associated with risks of CKD progression and mortality in persons with diabetes. Integrating multiple kidney biomarkers using a latent variable method of exploratory factor analysis could define distinct dimensions of kidney health and their associations with adverse outcomes. Methods: We conducted a factor analysis of 17 candidate urine and plasma biomarkers in 1256 participants with diabetes and eGFR 2 from the Chronic Renal Insufficiency Cohort (CRIC; N=701) and the REasons for Geographic And Racial Differences in Stroke (REGARDS; N=555) studies. We used Cox proportional hazards models to evaluate the associations of identified factors with CKD progression and mortality, adjusting for baseline clinical risk factors, eGFR, and albuminuria. Results: Three factor scores comprising ten biomarkers were identified: systemic inflammation and filtration (plasma TNF receptor-1 and TNF receptor-2, plasma soluble urokinase plasminogen activator receptor, and plasma symmetric dimethylarginine), tubular function (urine EGF, urine asymmetric dimethylarginine, and urine symmetric dimethylarginine), and tubular damage (urine α-1 microglobulin, urine kidney injury molecule-1, and urine monocyte chemoattractant protein-1). In CRIC, there were 244 incident ESKD events, 102 with ≥40% eGFR decline from baseline, and 259 deaths; in REGARDS, there were 121 incident ESKD events and 462 deaths. In CRIC, lower tubular function (hazard ratio per 1-SD, 0.36; 95% confidence interval, 0.25 to 0.52) and higher tubular damage (1.45; 1.18 to 1.78) scores were independently associated with higher CKD progression risk. Associations in REGARDS were weaker but directionally consistent (tubular function score [0.81; 0.47 to 1.39] and tubular damage score [1.12; 0.73 to 1.72]). Higher tubular damage (1.47; 1.15 to 1.87) scores were associated with higher mortality risk in CRIC, but not REGARDS (1.15; 0.96 to 1.38). Higher systemic inflammation and filtration factor scores were associated with higher mortality risk in both cohorts (CRIC: 1.35; 1.07 to 1.71; REGARDS: 1.41; 1.20 to 1.65). Conclusions: Three distinct kidney health dimensions were identified, and each associated with CKD progression and/or all-cause mortality in persons with diabetes and CKD.


  • Differential Effect of Hospitalization on Cystatin C– and Creatinine-Based Estimated GFR

    by Ian E. McCoy, Alan S. Go, Jesse Y. Hsu, Xiaoming Zhang, Anthony N. Muiru, Vallabh O. Shah, Matthew Weir, Hernan Rincon-Choles, Debbie L. Cohen, Amanda Anderson, et al.

    Key Points: Critical illness is known to acutely decrease eGFRdiff (estimation of GFR by cystatin C−estimation of GFR from serum creatinine [eGFRCr]), presumably because of loss of muscle mass falsely elevating eGFRCr. It is unknown whether this eGFRdiff effect occurs in all-cause hospitalizations and whether the effect persists after hospitalization. More hospitalization was associated with larger decreases in estimation of GFR by cystatin C compared with eGFRCr on measurements months after hospital discharge. Background: Cystatin C has entered mainstream clinical care as a measure of kidney function, joining serum creatinine, which has been used for almost a century. However, many physicians notice that estimation of GFR from serum creatinine (eGFRCr) and estimation of GFR by cystatin C (eGFRCys) values can differ considerably. Hospitalization with critical illness is known to acutely decrease eGFRdiff (eGFRCys−eGFRCr). However, whether this effect occurs in all-cause hospitalizations and persists after hospitalization is unknown. Methods: Among 5599 adult participants in the Chronic Renal Insufficiency Cohort study with serum creatinine and cystatin C measurements, we estimated the association of six categories of total days of hospitalization between annual study visits (never hospitalized, hospitalized e.g ., −3.30 [95% confidence interval, −5.48 to −1.13] ml/min per 1.73 m 2 for ≥42 days of hospitalization, test for trend P < 0.001), while eGFRCr remained relatively stable ( e.g ., −1.12 [−2.77 to 0.53] ml/min per 1.73 m 2 for ≥42 days of hospitalization, test for trend P = 0.21). The differential effect resulted in eGFRdiff becoming progressively more negative with more total days of hospitalization (test for trend P < 0.001). Conclusions: Prolonged or repeated hospitalization was associated with larger decreases in eGFRCys compared with eGFRCr on measurements months after hospital discharge.


  • Factors Associated With Non-vaccination for Influenza Among Patients With CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study

    by Junichi Ishigami, Bernard G. Jaar, Jeanne B. Charleston, James P. Lash, Julia Brown, Jing Chen, Katherine T. Mills, Jonathan J. Taliercio, Sheru Kansal, Deidra C. Crews, et al.


  • Open Access

    Conversion from Intermittent Hemodialysis to Peritoneal Dialysis in Metastatic Catheter-Related Bloodstream Infection

    by Mohamedanwar Ghandour, Ravi K. Thimmisetty, James Sondheimer, Nashat Imran, Zeenat Y. Bhat, Yahya Mohamed Osman-Malik

    Of all complications from central venous catheters (CVC) in end-stage renal disease (ESRD) patients, catheter-related bloodstream infection (CRBSI) is one of the most devastating consequences. The option of catheter salvage is not an effective measure with metastatic infections. However, in patients with severe vasculopathy and/or near end-stage vascular disease, preservation of the venous access should be given utmost importance as the luxury of utilizing another vascular site is markedly limited. Providing adequate renal replacement therapy in this group of patients can be remarkably challenging for nephrologists. We are presenting an ESRD patient with advanced vascular disease who developed metastatic CRBSI with worsening uremia who was successfully converted from intermittent hemodialysis (IHD) to peritoneal dialysis (PD). Our rationale was to minimize repeated intravascular procedures coupled with the presence of another intravascular device. This has led to a complete resolution of persistent bacteremia, with a steady improvement in the uremic state. Conversion from IHD to PD for persistent bacteremia with metastatic complications was seldom addressed in literature. In the absence of a significant contraindication to PD, it can be considered as a valid alternative possibility in order to interrupt this viscous cycle, especially in vasculopathic patients.

  • Risk for Chronic Kidney Disease Progression After Acute Kidney Injury: Findings From the Chronic Renal Insufficiency Cohort Study

    by Anthony N. Muiru, Jesse Y. Hsu, Xiaoming Zhang, Lawrence J. Appel, Jing Chen, Debbie L. Cohen, Paul E. Drawz, Barry I. Freedman, Alan S. Go, Jiang He, et al.

    Prior studies associating acute kidney injury (AKI) with more rapid subsequent loss of kidney function had methodological limitations, including inadequate control for differences between patients who had AKI and those who did not. To determine whether AKI is independently associated with subsequent kidney function trajectory among patients with chronic kidney disease (CKD). Multicenter prospective cohort study. United States. Patients with CKD (n = 3150). Hospitalized AKI was defined by a 50% or greater increase in inpatient serum creatinine (SCr) level from nadir to peak. Kidney function trajectory was assessed using estimated glomerular filtration rate (eGFR) based on SCr level (eGFRcr) or cystatin C level (eGFRcys) measured at annual study visits. During a median follow-up of 3.9 years, 433 participants had at least 1 AKI episode. Most episodes (92%) had stage 1 or 2 severity. There were decreases in eGFRcr (-2.30 [95% CI, -3.70 to -0.86] mL/min/1.73 m2) and eGFRcys (-3.61 [CI, -6.39 to -0.82] mL/min/1.73 m2) after AKI. However, in fully adjusted models, the decreases were attenuated to -0.38 (CI, -1.35 to 0.59) mL/min/1.73 m2 for eGFRcr and -0.15 (CI, -2.16 to 1.86) mL/min/1.73 m2 for eGFRcys, and the CI bounds included the possibility of no effect. Estimates of changes in eGFR slope after AKI determined by either SCr level (0.04 [CI, -0.30 to 0.38] mL/min/1.73 m2 per year) or cystatin C level (-0.56 [CI, -1.28 to 0.17] mL/min/1.73 m2 per year) also had CI bounds that included the possibility of no effect. Few cases of severe AKI, no adjudication of AKI cause, and lack of information about nephrotoxic exposures after hospital discharge. After pre-AKI eGFR, proteinuria, and other covariables were accounted for, the association between mild to moderate AKI and worsening subsequent kidney function in patients with CKD was small. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.


  • Open Access

    Metabolite profiling of CKD progression in the chronic renal insufficiency cohort study

    by Donghai Wen, Zihe Zheng, Aditya Surapaneni, Bing Yu, Linda Zhou, Wen Zhou, Dawei Xie, Haochang Shou, Julian Avila-Pacheco, Sahir Kalim, et al.

    BACKGROUND: Metabolomic profiling in individuals with chronic kidney disease (CKD) has the potential to identify novel biomarkers and provide insight into disease pathogenesis. METHODS: We examined the association between blood metabolites and CKD progression, defined as the subsequent development of end-stage renal disease (ESRD) or estimated glomerular filtrate rate (eGFR) halving, in 1,773 participants of the Chronic Renal Insufficiency Cohort (CRIC) study, 962 participants of the African-American Study of Kidney Disease and Hypertension (AASK), and 5,305 participants of the Atherosclerosis Risk in Communities (ARIC) study. RESULTS: In CRIC, more than half of the measured metabolites were associated with CKD progression in minimally adjusted Cox proportional hazards models, but the number and strength of associations were markedly attenuated by serial adjustment for covariates, particularly eGFR. Ten metabolites were significantly associated with CKD progression in fully adjusted models in CRIC; 3 of these metabolites were also significant in fully adjusted models in AASK and ARIC, highlighting potential markers of glomerular filtration (pseudouridine), histamine metabolism (methylimidazoleacetate), and azotemia (homocitrulline). Our findings also highlight N-acetylserine as a potential marker of kidney tubular function, with significant associations with CKD progression observed in CRIC and ARIC. CONCLUSION: Our findings demonstrate the application of metabolomics to identify potential biomarkers and causal pathways in CKD progression. FUNDING: This study was supported by the NIH (U01 DK106981, U01 DK106982, U01 DK085689, R01 DK108803, and R01 DK124399).


  • Association of Proximal Tubular Secretory Clearance with Long-Term Decline in Cognitive Function

    by Benjamin Lidgard, Nisha Bansal, Leila R. Zelnick, Andrew Hoofnagle, Jing Chen, Derek Colaizzo, Mirela Dobre, Katherine T. Mills, Anna C. Porter, Sylvia E. Rosas, et al.

    Background People with chronic kidney disease (CKD) are at high risk for cognitive impairment and progressive cognitive decline. Retention of protein-bound organic solutes that are normally removed by tubular secretion is hypothesized to contribute to cognitive impairment in CKD. Methods We followed 2362 participants who were initially free of cognitive impairment and stroke in the prospective Chronic Renal Insufficiency Cohort (CRIC) Study. We estimated tubular secretory clearance by the 24-hour kidney clearances of eight endogenous solutes that are primarily eliminated by tubular secretion. CRIC study investigators assessed participants’ cognitive function annually using the Modified Mini-Mental State (3MS) Examination. Cognitive decline was defined as a sustained decrease of more than five points in the 3MS score from baseline. Using Cox regression models adjusted for potential confounders, we analyzed associations between secretory solute clearances, serum solute concentrations, and cognitive decline. Results The median number of follow-up 3MS examinations was six per participant. There were 247 incident cognitive decline events over a median of 9.1 years of follow-up. Lower kidney clearances of five of the eight secretory solutes (cinnamoylglycine, isovalerylglycine, kynurenic acid, pyridoxic acid, and tiglylglycine) were associated with cognitive decline after adjustment for baseline eGFR, proteinuria, and other confounding variables. Effect sizes ranged from a 17% to a 34% higher risk of cognitive decline per 50% lower clearance. In contrast, serum concentrations of the solutes were not associated with cognitive decline. Conclusions Lower kidney clearances of secreted solutes are associated with incident global cognitive decline in a prospective study of CKD, independent of eGFR. Further work is needed to determine the domains of cognition most affected by decreased secretory clearance and the mechanisms of these associations.


  • Open Access

    Calcific Uremic Arteriolopathy: A Case Series and Review from an Inner-City Tertiary University Center in End-Stage Renal Disease Patients on Renal Replacement Therapy

    by Mohamed Omer, Zeenat Yousuf Bhat, Nanette Fonte, Nashat Imran, James Sondheimer, Yahya Osman‐Malik

    Background and Objectives. Calcific uremic arteriolopathy (CUA) is a rare complication seen, especially in patients undergoing renal replacement therapy (RRT) with high morbidity and mortality. CUA treatment remains challenging. The study evaluated CUA's multifaceted treatment efficacy. Materials and Methods. 24 patients with CUA and on RRT were evaluated at Detroit Medical Center from 2007 to 2016. Skin biopsy was used in almost all patients, along with the radiological and clinical findings. The patients clinical and paraclinical data were retrieved from the electronic medical records. The effect of treatment modalities and the underlying hyperparathyroidism management were compared to the clinical outcomes using appropriate statistical tests. Results. Twenty-one patients were on hemodialysis, two patients received renal transplants, and one patient was on peritoneal dialysis. Diabetes mellitus was the most prevalent cause of ESRD. The parathyroid hormone level (PTH) was elevated in 22 patients. Fifteen patients were diagnosed 2 weeks or more prior to skin lesion onset. Twenty-two and thirteen patients received sodium thiosulphate and cinacalcet, respectively. Patients with lower PTH and the calcium-phosphate product levels had a relatively better outcome of CUA. Conclusions. A multifaceted approach may play a role in treating CUA. Referral to a nephrologist may aid in the early diagnosis and prompt management of CUA.


  • Slope of Kidney Function and Its Association with Longitudinal Mortality and Cardiovascular Disease among Individuals with CKD

    by Paula F. Orlandi, Dawei Xie, Wei Yang, Jordana B. Cohen, Rajat Deo, Ana C. Ricardo, Sarah Schrauben, Xue Wang, L. Lee Hamm, Jiang He, et al.

    Significance Statement: Among individuals with CKD, decreases in eGFR, or increases that are steeper than the average loss, have been associated with increased risks of death and cardiovascular events. Sarcopenia and chronic illness might explain why apparent eGFR improvement relates to poor outcomes. The authors investigated the association between slopes of eGFR (defined with yearly eGFR) and the risks of death and cardiovascular events in a prospective cohort of adults with CKD. They found that declines in eGFR greater than the average eGFR loss were associated with increased risks of death and cardiovascular events, despite multiple adjustments. However, neither rises in eGFR nor losses smaller than the average eGFR loss were associated with increases in such risks. These findings suggest that, in CKD, improving eGFR might not be associated with concerning outcomes. Background: Slopes of eGFR have been associated with increased risks of death and cardiovascular events in a U-shaped fashion. Poor outcomes in individuals with rising eGFR are potentially attributable to sarcopenia, hemodilution, and other indicators of clinical deterioration. Methods: To investigate the association between eGFR slopes and risks of death or cardiovascular events, accounting for multiple confounders, we studied 2738 individuals with moderate to severe CKD participating in the multicenter Chronic Renal Insufficiency Cohort (CRIC) Study. We used linear, mixed-effects models to estimate slopes with up to four annual eGFR assessments, and Cox proportional hazards models to investigate the association between slopes and the risks of death and cardiovascular events. Results: Slopes of eGFR had a bell-shaped distribution (mean [SD], −1.5 [−2] ml/min per 1.73 m2 per year). Declines of eGFR that were steeper than the average decline associated with progressively increasing risks of death (hazard ratio [HR], 1.23; 95% confidence interval [95% CI], 1.09 to 1.39; for a slope 1 SD below the average) and cardiovascular events (HR, 1.19; 95% CI, 1.03 to 1.38). Rises of eGFR or declines lower than the average decline were not associated with the risk of death or cardiovascular events. Conclusions: In a cohort of individuals with moderate to severe CKD, we observed steep declines of eGFR were associated with progressively increasing risks of death and cardiovascular events; however, we found no increased risks associated with eGFR improvement. These findings support the potential value of eGFR slopes in clinical assessment of adults with CKD.


  • Anemia and Incident End-Stage Kidney Disease

    by Santosh L. Saraf, Jesse Y. Hsu, Ana C. Ricardo, Rupal Mehta, Jing Chen, Teresa K. Chen, Michael J. Fischer, Lee Hamm, James Sondheimer, Matthew R. Weir, et al.

    Background: CKD progression can be a cause and potentially a consequence of anemia. Previous studies suggesting that anemia is associated with CKD progression have not used methodologic approaches to address time-dependent confounding. Methods: We evaluated the association of anemia (defined using World Health Organization criteria of hemoglobin <12 g/dl in women and <13 g/dl in men) with incident ESKD and all-cause death in individuals with CKD using data from the Chronic Renal Insufficiency Cohort Study. Marginal structural models were used to account for time-dependent confounding. Results: Among 3919 participants, 1859 (47%) had anemia at baseline. Over median follow-up of 7.8 years, we observed 1010 ESKD events and 994 deaths. In multivariable analyses, individuals with anemia had higher risk for ESKD compared with those without (HR, 1.62; 95% CI, 1.24 to 2.11). In stratified analyses, the increased risk for incident ESKD with anemia was observed in males (HR, 2.15; 95% CI, 1.53 to 3.02) but not females (HR, 1.20; 95% CI, 0.82 to 1.78). The association between anemia and ESKD was significant among all racial/ethnic groups except non-Hispanic blacks (non-Hispanic white, HR, 2.16; 95% CI, 1.53 to 3.06; Hispanic, HR, 1.92; 95% CI, 1.04 to 3.51; others, HR, 2.94; 95% CI, 1.16 to 7.44; non-Hispanic black, HR, 1.39; 95% CI, 0.95 to 2.02). There was no association between anemia and all-cause death. Conclusions: In this cohort, anemia was independently associated with increased risk for incident ESKD. Future work is needed to evaluate the mechanisms by which anemia leads to CKD progression as well as the effect of novel therapeutic agents to treat anemia.